Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium + lactobacillus + enterococcus + mesalamine
- Development stage
- Unknown
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This is a combination therapy consisting of mesalamine (5-aminosalicylic acid) and a probiotic mixture containing Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis. The mesalamine component inhibits inflammatory mediators such as prostaglandin E2, leukotriene B4, and platelets in the serum of patients with inflammatory bowel disease (IBD), thereby reducing inflammation. The probiotic component helps improve intestinal mucosal barrier function, correct intestinal microecological disorders, promote the secretion of anti-inflammatory factors, and inhibit the growth of harmful bacteria. This combination has shown greater efficacy than mesalamine alone in treating mild to moderate inflammatory bowel diseases, particularly Crohn's disease and ulcerative colitis.
- Brand names
- Bifid Triple Viable + Etiasa
- Other names
- Live combined Bifidobacterium, Lactobacillus and Enterococcus capsules with mesalamineMesalazine combined with probioticsMesalamine with Bifid Triple Viable Capsules
02
Targets
PGE2 (Prostaglandin E2)IL10 (Interleukin-10)TNFA (Tumor necrosis factor alpha (soluble))IL-6 (Interleukin 6)
Beyond the preview
Go deeper on bifidobacterium + lactobacillus + enterococcus + mesalamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium + lactobacillus + enterococcus + mesalamine.